Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry
Identifieur interne : 000966 ( Main/Exploration ); précédent : 000965; suivant : 000967Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry
Auteurs : X. Mariette [France] ; F. Tubach [France] ; H. Bagheri [France] ; M. Bardet [France] ; J M Berthelot [France] ; P. Gaudin [France] ; D. Heresbach [France] ; A. Martin [France] ; T. Schaeverbeke [France] ; D. Salmon [France] ; M. Lemann [France] ; O. Hermine [France] ; M. Raphael [France] ; P. Ravaud [France]Source :
- Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2010-02.
Abstract
Objective: To describe cases of lymphoma associated with anti-TNF therapy, identify risk factors, estimate the incidence and compare the risks for different anti-TNF agents. Methods: A national prospective registry was designed (Research Axed on Tolerance of bIOtherapies; RATIO) to collect all cases of lymphoma in French patients receiving anti-TNF therapy from 2004 to 2006, whatever the indication. A case–control analysis was conducted including two controls treated with anti-TNF per case and an incidence study of lymphoma with the French population was used as the reference. Results: 38 cases of lymphoma, 31 non-Hodgkin’s lymphoma (NHL) (26 B cell and five T cell), five Hodgkin’s lymphoma (HL) and two Hodgkin’s-like lymphoma were collected. Epstein–Barr virus was detected in both of two Hodgkin’s-like lymphoma, three of five HL and one NHL. Patients receiving adalimumab or infliximab had a higher risk than those treated with etanercept: standardised incidence ratio (SIR) 4.1 (2.3–7.1) and 3.6 (2.3–5.6) versus 0.9 (0.4–1.8). The exposure to adalimumab or infliximab versus etanercept was an independent risk factor for lymphoma in the case–control study: odds ratio 4.7 (1.3–17.7) and 4.1 (1.4–12.5), respectively. The sex and age-adjusted incidence rate of lymphoma was 42.1 per 100 000 patient-years. The SIR was 2.4 (95% CI 1.7 to 3.2). Conclusion: The two to threefold increased risk of lymphoma in patients receiving anti-TNF therapy is similar to that expected for such patients with severe inflammatory diseases. Some lymphomas associated with immunosuppression may occur, and the risk of lymphoma is higher with monoclonal-antibody therapy than with soluble-receptor therapy.
Url:
- https://api.istex.fr/document/733F58FA17CA878BEB83478B8B10B3590B340E75/fulltext/pdf
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2925048
DOI: 10.1136/ard.2009.117762
Affiliations:
- France
- Aquitaine
- Bordeaux, Grenoble, Nantes, Orléans, Paris, Rennes, Saint-Brieuc, Toulouse
- Université Bordeaux II
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001784
- to stream Istex, to step Curation: 001784
- to stream Istex, to step Checkpoint: 000150
- to stream Pmc, to step Corpus: 000200
- to stream Pmc, to step Curation: 000198
- to stream Pmc, to step Checkpoint: 000115
- to stream Ncbi, to step Merge: 000238
- to stream Ncbi, to step Curation: 000238
- to stream Ncbi, to step Checkpoint: 000238
- to stream Main, to step Merge: 000967
- to stream Main, to step Curation: 000966
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry</title><author><name sortKey="Mariette, X" sort="Mariette, X" uniqKey="Mariette X" first="X" last="Mariette">X. Mariette</name></author><author><name sortKey="Tubach, F" sort="Tubach, F" uniqKey="Tubach F" first="F" last="Tubach">F. Tubach</name></author><author><name sortKey="Bagheri, H" sort="Bagheri, H" uniqKey="Bagheri H" first="H" last="Bagheri">H. Bagheri</name></author><author><name sortKey="Bardet, M" sort="Bardet, M" uniqKey="Bardet M" first="M" last="Bardet">M. Bardet</name></author><author><name sortKey="Berthelot, J M" sort="Berthelot, J M" uniqKey="Berthelot J" first="J M" last="Berthelot">J M Berthelot</name></author><author><name sortKey="Gaudin, P" sort="Gaudin, P" uniqKey="Gaudin P" first="P" last="Gaudin">P. Gaudin</name></author><author><name sortKey="Heresbach, D" sort="Heresbach, D" uniqKey="Heresbach D" first="D" last="Heresbach">D. Heresbach</name></author><author><name sortKey="Martin, A" sort="Martin, A" uniqKey="Martin A" first="A" last="Martin">A. Martin</name></author><author><name sortKey="Schaeverbeke, T" sort="Schaeverbeke, T" uniqKey="Schaeverbeke T" first="T" last="Schaeverbeke">T. Schaeverbeke</name></author><author><name sortKey="Salmon, D" sort="Salmon, D" uniqKey="Salmon D" first="D" last="Salmon">D. Salmon</name></author><author><name sortKey="Lemann, M" sort="Lemann, M" uniqKey="Lemann M" first="M" last="Lemann">M. Lemann</name></author><author><name sortKey="Hermine, O" sort="Hermine, O" uniqKey="Hermine O" first="O" last="Hermine">O. Hermine</name></author><author><name sortKey="Raphael, M" sort="Raphael, M" uniqKey="Raphael M" first="M" last="Raphael">M. Raphael</name></author><author><name sortKey="Ravaud, P" sort="Ravaud, P" uniqKey="Ravaud P" first="P" last="Ravaud">P. Ravaud</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:733F58FA17CA878BEB83478B8B10B3590B340E75</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1136/ard.2009.117762</idno><idno type="url">https://api.istex.fr/document/733F58FA17CA878BEB83478B8B10B3590B340E75/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001784</idno><idno type="wicri:Area/Istex/Curation">001784</idno><idno type="wicri:Area/Istex/Checkpoint">000150</idno><idno type="wicri:doubleKey">0003-4967:2010:Mariette X:lymphoma:in:patients</idno><idno type="wicri:source">PMC</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2925048</idno><idno type="RBID">PMC:2925048</idno><idno type="wicri:Area/Pmc/Corpus">000200</idno><idno type="wicri:Area/Pmc/Curation">000198</idno><idno type="wicri:Area/Pmc/Checkpoint">000115</idno><idno type="wicri:Area/Ncbi/Merge">000238</idno><idno type="wicri:Area/Ncbi/Curation">000238</idno><idno type="wicri:Area/Ncbi/Checkpoint">000238</idno><idno type="wicri:doubleKey">0003-4967:2009:Mariette X:lymphoma:in:patients</idno><idno type="wicri:Area/Main/Merge">000967</idno><idno type="wicri:Area/Main/Curation">000966</idno><idno type="wicri:Area/Main/Exploration">000966</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry</title><author><name sortKey="Mariette, X" sort="Mariette, X" uniqKey="Mariette X" first="X" last="Mariette">X. Mariette</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Bicêtre, Service de rhumatologie, Université Paris-Sud 11, INSERM U802, Le Kremlin-Bicêtre</wicri:regionArea><wicri:noRegion>Le Kremlin-Bicêtre</wicri:noRegion><wicri:noRegion>Le Kremlin-Bicêtre</wicri:noRegion></affiliation></author><author><name sortKey="Tubach, F" sort="Tubach, F" uniqKey="Tubach F" first="F" last="Tubach">F. Tubach</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Université Paris 7 Denis Diderot, UFR de médecine; INSERM, U738; AP-HP, Hôpital Bichat, Département d’Epidémiologie, Biostatistique et Recherche Clinique, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Bagheri, H" sort="Bagheri, H" uniqKey="Bagheri H" first="H" last="Bagheri">H. Bagheri</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d’Informations sur le Médicament, Unité de Pharmacoépidémiologie, EA 3696, Université de Toulouse, Faculté de Médecine, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Bardet, M" sort="Bardet, M" uniqKey="Bardet M" first="M" last="Bardet">M. Bardet</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Hôpital de la Source, Service de médecine interne et rhumatologie, Orléans</wicri:regionArea><placeName><settlement type="city">Orléans</settlement></placeName></affiliation></author><author><name sortKey="Berthelot, J M" sort="Berthelot, J M" uniqKey="Berthelot J" first="J M" last="Berthelot">J M Berthelot</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Hôtel Dieu, Service de rhumatologie, Nantes</wicri:regionArea><placeName><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name sortKey="Gaudin, P" sort="Gaudin, P" uniqKey="Gaudin P" first="P" last="Gaudin">P. Gaudin</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Centre Hospitalo-Universitaire, Service de rhumatologie, Grenoble</wicri:regionArea><placeName><settlement type="city">Grenoble</settlement></placeName></affiliation></author><author><name sortKey="Heresbach, D" sort="Heresbach, D" uniqKey="Heresbach D" first="D" last="Heresbach">D. Heresbach</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Pontchaillou, Service des maladies digestives, Rennes</wicri:regionArea><placeName><settlement type="city">Rennes</settlement></placeName></affiliation></author><author><name sortKey="Martin, A" sort="Martin, A" uniqKey="Martin A" first="A" last="Martin">A. Martin</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Hôpital de Saint Brieuc, Service de rhumatologie, Saint Brieuc</wicri:regionArea><placeName><settlement type="city">Saint-Brieuc</settlement></placeName></affiliation></author><author><name sortKey="Schaeverbeke, T" sort="Schaeverbeke, T" uniqKey="Schaeverbeke T" first="T" last="Schaeverbeke">T. Schaeverbeke</name><affiliation wicri:level="4"><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Pellegrin, Service de rhumatologie, Université Bordeaux II, Bordeaux</wicri:regionArea><placeName><settlement type="city">Bordeaux</settlement></placeName><orgName type="university">Université Bordeaux II</orgName><placeName><settlement type="city">Bordeaux</settlement><region type="region" nuts="2">Aquitaine</region></placeName></affiliation></author><author><name sortKey="Salmon, D" sort="Salmon, D" uniqKey="Salmon D" first="D" last="Salmon">D. Salmon</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>AP-HP, Hôpital Cochin, Service de médecine interne, Université Paris V, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Lemann, M" sort="Lemann, M" uniqKey="Lemann M" first="M" last="Lemann">M. Lemann</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>AP-HP, Hôpital Saint Louis, Service de gastro-entérologie, Université Paris 7, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Hermine, O" sort="Hermine, O" uniqKey="Hermine O" first="O" last="Hermine">O. Hermine</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>AP-HP, Hôpital Necker, Service d’hématologie, CNRS UMR 8143, Université Paris V, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Raphael, M" sort="Raphael, M" uniqKey="Raphael M" first="M" last="Raphael">M. Raphael</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>AP-HP, Hôpital Bicêtre, Laboratoire d’hématologie, Université Paris-Sud 11, Le Kremlin-Bicêtre</wicri:regionArea><wicri:noRegion>Le Kremlin-Bicêtre</wicri:noRegion><wicri:noRegion>Le Kremlin-Bicêtre</wicri:noRegion></affiliation></author><author><name sortKey="Ravaud, P" sort="Ravaud, P" uniqKey="Ravaud P" first="P" last="Ravaud">P. Ravaud</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Université Paris 7 Denis Diderot, UFR de médecine; INSERM, U738; AP-HP, Hôpital Bichat, Département d’Epidémiologie, Biostatistique et Recherche Clinique, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of the Rheumatic Diseases</title><title level="j" type="abbrev">Ann Rheum Dis</title><idno type="ISSN">0003-4967</idno><idno type="eISSN">1468-2060</idno><imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><date type="published" when="2010-02">2010-02</date><biblScope unit="volume">69</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="400">400</biblScope></imprint><idno type="ISSN">0003-4967</idno></series><idno type="istex">733F58FA17CA878BEB83478B8B10B3590B340E75</idno><idno type="DOI">10.1136/ard.2009.117762</idno><idno type="href">annrheumdis-69-400.pdf</idno><idno type="ArticleID">ar117762</idno><idno type="PMID">19828563</idno><idno type="local">annrheumdis;69/2/400</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0003-4967</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Objective: To describe cases of lymphoma associated with anti-TNF therapy, identify risk factors, estimate the incidence and compare the risks for different anti-TNF agents. Methods: A national prospective registry was designed (Research Axed on Tolerance of bIOtherapies; RATIO) to collect all cases of lymphoma in French patients receiving anti-TNF therapy from 2004 to 2006, whatever the indication. A case–control analysis was conducted including two controls treated with anti-TNF per case and an incidence study of lymphoma with the French population was used as the reference. Results: 38 cases of lymphoma, 31 non-Hodgkin’s lymphoma (NHL) (26 B cell and five T cell), five Hodgkin’s lymphoma (HL) and two Hodgkin’s-like lymphoma were collected. Epstein–Barr virus was detected in both of two Hodgkin’s-like lymphoma, three of five HL and one NHL. Patients receiving adalimumab or infliximab had a higher risk than those treated with etanercept: standardised incidence ratio (SIR) 4.1 (2.3–7.1) and 3.6 (2.3–5.6) versus 0.9 (0.4–1.8). The exposure to adalimumab or infliximab versus etanercept was an independent risk factor for lymphoma in the case–control study: odds ratio 4.7 (1.3–17.7) and 4.1 (1.4–12.5), respectively. The sex and age-adjusted incidence rate of lymphoma was 42.1 per 100 000 patient-years. The SIR was 2.4 (95% CI 1.7 to 3.2). Conclusion: The two to threefold increased risk of lymphoma in patients receiving anti-TNF therapy is similar to that expected for such patients with severe inflammatory diseases. Some lymphomas associated with immunosuppression may occur, and the risk of lymphoma is higher with monoclonal-antibody therapy than with soluble-receptor therapy.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Aquitaine</li></region><settlement><li>Bordeaux</li><li>Grenoble</li><li>Nantes</li><li>Orléans</li><li>Paris</li><li>Rennes</li><li>Saint-Brieuc</li><li>Toulouse</li></settlement><orgName><li>Université Bordeaux II</li></orgName></list><tree><country name="France"><noRegion><name sortKey="Mariette, X" sort="Mariette, X" uniqKey="Mariette X" first="X" last="Mariette">X. Mariette</name></noRegion><name sortKey="Bagheri, H" sort="Bagheri, H" uniqKey="Bagheri H" first="H" last="Bagheri">H. Bagheri</name><name sortKey="Bardet, M" sort="Bardet, M" uniqKey="Bardet M" first="M" last="Bardet">M. Bardet</name><name sortKey="Berthelot, J M" sort="Berthelot, J M" uniqKey="Berthelot J" first="J M" last="Berthelot">J M Berthelot</name><name sortKey="Gaudin, P" sort="Gaudin, P" uniqKey="Gaudin P" first="P" last="Gaudin">P. Gaudin</name><name sortKey="Heresbach, D" sort="Heresbach, D" uniqKey="Heresbach D" first="D" last="Heresbach">D. Heresbach</name><name sortKey="Hermine, O" sort="Hermine, O" uniqKey="Hermine O" first="O" last="Hermine">O. Hermine</name><name sortKey="Lemann, M" sort="Lemann, M" uniqKey="Lemann M" first="M" last="Lemann">M. Lemann</name><name sortKey="Martin, A" sort="Martin, A" uniqKey="Martin A" first="A" last="Martin">A. Martin</name><name sortKey="Raphael, M" sort="Raphael, M" uniqKey="Raphael M" first="M" last="Raphael">M. Raphael</name><name sortKey="Ravaud, P" sort="Ravaud, P" uniqKey="Ravaud P" first="P" last="Ravaud">P. Ravaud</name><name sortKey="Salmon, D" sort="Salmon, D" uniqKey="Salmon D" first="D" last="Salmon">D. Salmon</name><name sortKey="Schaeverbeke, T" sort="Schaeverbeke, T" uniqKey="Schaeverbeke T" first="T" last="Schaeverbeke">T. Schaeverbeke</name><name sortKey="Tubach, F" sort="Tubach, F" uniqKey="Tubach F" first="F" last="Tubach">F. Tubach</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/France/explor/LeHavreV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000966 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000966 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/France
|area= LeHavreV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:733F58FA17CA878BEB83478B8B10B3590B340E75
|texte= Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry
}}
| This area was generated with Dilib version V0.6.25. |  |